Search clinical trials for: EGFR TKIs (EGF816)

Total 1639 results

Novartis Pharmaceuticals

Completed

A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies

Advanced Non-small Cell Lung Cancer

Spain, Canada, Germany, Korea, Republic of, Taiwan, United States, Japan, Netherlands, Singapore
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

Spain, Japan, Korea, Republic of, Taiwan, Netherlands, United States, Italy, Canada, Singapore
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.

Non Small Cell Lung Cancer

Canada, Spain, Australia, Singapore, Germany, Italy, Korea, Republic of, Norway, Taiwan, United States, France
Novartis Pharmaceuticals

Withdrawn

Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations

Carcinoma, Non-small Cell Lung
University of Cologne

Completed

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations (EATON)

Bronchial Neoplasms

Spain, Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

EGFR-mutant Non-small Cell Lung Cancer

Taiwan, Germany, Canada, Italy, Singapore, Hong Kong
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

Spain, Singapore, Germany, Switzerland, Australia, France, Italy, United States
Massachusetts General Hospital
Novartis

Active, not recruiting

A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
Novartis Pharmaceuticals

Recruiting

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Advanced Solid Tumors Which Are cMET-dependent

Germany, Korea, Republic of, Belgium, Italy, Singapore, United States, Denmark, Spain, France, Canada
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
Second Xiangya Hospital of Central South University
The First Affiliated Hospital of Nanchang University; Xiangya Hospital of Central... and other collaborators

Recruiting

Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study) (PRECISE)

Lung Cancer, Non-small Cell | Circulating Tumor DNA | EGFR Gene Mutation | EGFR-TKI Resistant Mutation | Primary Resistance

China
Affiliated Hospital of Jiangnan University

Recruiting

Pamiparib (BGB-290) Was Used in EGFR-TkIs Resistant Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung | EGF-R Positive Non-Small Cell Lung Cancer

China
Dr Joanne CHIU

Recruiting

Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC

ALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung Cancer

Hong Kong
Peking University
Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (VISIONARY)

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Esophageal Squamous Cell Carcinoma | Biliary Tract Neoplasms | Unknown Primary Cancer | Digestive Cancer

China
Guangdong Association of Clinical Trials

Recruiting

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study (BELLA)

NSCLC

China
Shanghai Cancer Hospital, China

Recruiting

Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs

Lung Cancer Stage IV

China
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Prospective Study (SELECT-2)

Adenocarcinoma | Carcinoma | Non-Small-Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Fudan University

Completed

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

NSCLC Stage IV | EGFR Activating Mutation

China
Tian Xie
LinkDoc Technology (Beijing) Co. Ltd.

Active, not recruiting

Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC：Retrospective Study (SELECT-1)

Carcinoma, Non-Small-Cell Lung

China
Sumitomo Pharma America, Inc.

Completed

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Advanced Solid Tumors | Recurrent Ovarian Carcinoma | Colorectal Carcinoma | EGFR Positive Non-small Cell Lung Cancer | BRAF-Mutated Melanoma

United States
National Taiwan University Hospital

Completed

Optimal EGFR TKIs Treatment Strategies for Lung Adenocarcinoma Harboring EGFR Exon 19 Deletion Variants

Tumor Progression | EGFR Exon 19 Mutation

Taiwan
Sun Yat-sen University

Completed

Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment (EGFR-TKIs)

Non-small Cell Lung Cancer

China
Second Affiliated Hospital of Nanchang University
Nanchang University

Unknown

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

Non-small Cell Lung Cancer | EGFR Gene Mutation

China
Guangdong Association of Clinical Trials

Unknown

Pemetrexed vs Pemetrexed Plus Cisplatin in EGFR-mutant NSCLC Patients After First Line EGFR-TKIs Failure

Non-small Cell Lung Cancer

China
Hellenic Oncology Research Group

Unknown

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Non Small Cell Lung Cancer

Greece
The First Affiliated Hospital of Soochow University
Affiliated Hospital of Jiangnan University; Chia Tai Tianqing Pharmaceutical... and other collaborators

Unknown

Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer

Non-Small-Cell Lung

China
Xinqiao Hospital of Chongqing

Terminated

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC (CERTAIN)

Non Small Cell Lung Cancer

China
First Hospital of Shijiazhuang City

Unknown

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Carcinoma | Non-small Cell Lung Cancer | Lung Neoplasm

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Daping Hospital and the Research Institute of Surgery...

Completed

Combination of Metformin With Gefitinib to Treat NSCLC (CGMT)

NSCLC | Advanced Cancer | EGFR Gene Amplification | Stage IV NSCLC | Stage IIIB NSCLC

China
Guangdong Association of Clinical Trials
Boehringer Ingelheim

Unknown

Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in China

Carcinoma, Non-Small-Cell Lung

China
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
China Medical University, China
General Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... and other collaborators

Unknown

β-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC

Non Small Cell Lung Cancer
Peking University Third Hospital

Unknown

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer

China
Chinese Academy of Sciences
Guangdong Academy of Medical Sciences; West China Hospital; Shanghai Pulmonary...

Unknown

Therapeutic Resistance Prediction of Tyrosine Kinase Inhibitors

Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC (effect)

EGFR Gene Mutation
Zhejiang Cancer Hospital

Unknown

Acquired Resistant Mechanism of the First-generation EGFR TKIs

Non-small Cell Lung Cancer | Aquired Resistance | EGFR TKIs

China
Armando Santoro, MD

Completed

Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

NON-SMALL-CELL LUNG CANCER

Italy
Ulsan University Hospital
AstraZeneca

Unknown

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Lung Neoplasms

Korea, Republic of
Sun Yat-sen University

Completed

Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC

Non-small Cell Lung Cancer

China
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
Samsung Medical Center
AstraZeneca

Unknown

Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

EGFR Mutation Positive Non-small Cell Lung Cancer

Korea, Republic of
Peking Union Medical College Hospital

Unknown

Study of Chemotherapy Sequenced by or Combined With EGFR-TKIs for NSCLC Patients Failed to EGFR-TKIs Therapy

Non Small Cell Lung Cancer

China
Chinese PLA General Hospital

Unknown

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Neoplasms, Lung | Carcinoma, Non-Small Cell Lung | Drug Therapy | Genes, EGFR

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Fujian Cancer Hospital

Not yet recruiting

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Leptomeningeal Metastasis

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV

Search clinical trials for: EGFR TKIs (EGF816)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cote d'Ivoire

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations